ALCAT1 Inhibitor Compounds for Mitochondrial Dysfunction Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can inhibit ALCAT1 activity to treat aging and age-related diseases such as type 2 diabetes, diabetic complications, cardiovascular diseases, neurodegenerative diseases, and other disorders associated with mitochondrial dysfunction.
Innovation Solution
Development of compounds according to formula (I) that inhibit ALCAT1 activity, which are administered in a pharmaceutical composition to target and down-regulate ALCAT1, thereby mitigating mitochondrial dysfunction and related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ALCAT1 is overexpressed, then cardiolipin remodeling is enhanced, but mitochondrial dysfunction and oxidative stress increase
Solution Approach 1:
The patent applies parameter changes by developing compounds that modify ALCAT1 activity through specific chemical interactions. The inhibitors change the enzymatic parameters of ALCAT1, reducing its catalytic activity toward cardiolipin remodeling, thereby decreasing oxidative stress while maintaining beneficial metabolic functions.
Solution Approach 2:
The patent introduces chemical compounds as intermediary substances that mediate between ALCAT1 and its substrate (cardiolipin). These compounds act as inhibitors, interfering with the enzyme-substrate interaction to reduce harmful cardiolipin remodeling while preserving other physiological functions.
2Object-affected harmful factors
If ALCAT1 is inhibited, then oxidative stress is reduced, but mitochondrial fusion may be impaired
Solution Approach 1:
The patent employs parameter changes by carefully controlling the degree and specificity of ALCAT1 inhibition. The compounds are designed to modulate enzymatic activity parameters to achieve selective inhibition of harmful cardiolipin remodeling while preserving essential mitochondrial fusion functions through MFN2.
Solution Approach 2:
The patent applies local quality by achieving selective inhibition of specific ALCAT1 functions. The inhibitors are designed to target specific substrate interactions (cardiolipin remodeling) while leaving other ALCAT1-dependent processes (such as mitochondrial fusion support) unaffected, thereby maintaining local functional differentiation.
3Reliability
If ALCAT1 is inhibited, then mitochondrial fragmentation is prevented, but DHA content in cardiolipin may increase
Solution Approach 1:
The patent introduces chemical compounds as intermediary substances that mediate the interaction between ALCAT1 and cardiolipin. These inhibitors specifically block the enzymatic conversion that increases DHA content, thereby preventing mitochondrial fragmentation while controlling lipid composition changes.
Solution Approach 2:
The patent converts the potential harmful effect of increased DHA content (which can lead to lipid peroxidation) into a beneficial outcome by selectively inhibiting ALCAT1. The inhibition prevents excessive DHA incorporation while maintaining adequate levels for mitochondrial function, thereby transforming a potential harm into a protective effect.
Data Source
AI summary
Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.